Compounds and therapeutics uses thereof

A compound of formula (I) or a pharmaceutically acceptable salt thereof:

• wherein L represents a binding moiety selected from an antibody or antigen binding fragment thereof;
• S1 represents a spacer selected from a —(CH2)a— or —(CH2)b—(CH2—CH2—O)c—(CH2)d— group, wherein one to ten of said —CH2— groups may optionally be substituted by one or more groups selected from —O—, —S—, ═N(H)—, —C(═O)—, —C(O)NH—, —NHC(O)—, cyclohexyl or pyrrolidine-2,5-dione;
• a represents an integer selected from 1 to 35;
• b represents an integer selected from 0 to 5;
• c represents an integer selected from 1 to 20;
• d represents an integer selected from 1 to 20;
• S2 represents a spacer selected from a —(CH2)e— or —(CH2)f—(CH2—CH2—O)g—(CH2)h— group, wherein one to three of said —CH2— groups may optionally be substituted by one or more groups selected from —N(H)—, —C(O)NH— and —NHC(O)—;
• e represents an integer selected from 1 to 15;
• f represents an integer selected from 1 to 10;
• g represents an integer selected from 1 to 20;
• h represents an integer selected from 1 to 5;
• z represents an integer selected from 1 to 30;
• X1 represents an antibody or antigen binding fragment attachment moiety;
• Y1 and Y2 independently represent a bond, —O—, —S—, —NH—, —NHC(O)—, —C(O)NH—, —OC(O)—, —C(O)O—, —SC(O)—, —C(O)S—, —NHSO2—, —SO2NH— or —NHC(O)NH— group;
• F represents a carbohydrate molecule capable of binding to a human anti-alpha-galactosyl antibody;
• m represents an integer selected from 1 to 5;
• and
• Cy represents phenyl, biphenyl, triphenyl, wherein when Cy represents biphenyl or triphenyl said —Y1—S1—X1-L group may be present on any of said phenyl rings and said [F—S2—Y2]m— group or groups may be present on any of said phenyl rings.